---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-069533"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2023-12-12T23:59:59+00:00"
generated_at: "2026-06-07T14:21:21.677265+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# FDA grants Fast Track Designation to Candel's CAN-2409 for pancreatic cancer

## Summary
- FDA Fast Track Designation for CAN-2409 (adenovirus immunotherapy) plus valacyclovir in pancreatic ductal adenocarcinoma (PDAC) to improve overall survival.
- Phase 2 interim data (Nov 2023): 71.4% estimated survival at 24 and 36 months with CAN-2409 + SoC vs 16.7% for SoC alone in borderline resectable PDAC.
- Updated overall survival data from interim analysis expected Q2 2024.
- CAN-2409 shown to activate immunologic antitumoral response in 'cold' tumors.

## SEC filing metadata
- accession: 0000950170-23-069533
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2023-12-12T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017023069533/0000950170-23-069533-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017023069533/cadl-20231212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-069533
- JSON: https://secwatch.observer/filing/0000950170-23-069533.json
- Plain text: https://secwatch.observer/filing/0000950170-23-069533.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.